Table 1 The composition of partnerships (infectious disease only)

Infectious Disease Partnership (N=3,001)

Avg yearly count: 227

Avg yearly count: 193

Avg yearly count: 518

Avg yearly count: 254

Entity Type^b

The ownership of the target company

     Public

Involving only publicly owned companies

30

15%

48

25%

81

16%

*

56

22%

     Private

Involving only privately owned companies

35

18%

24

12%

81

16%

*

36

14%

     Public + Private

Involving both publicly and privately owned companies

59

30%

61

32%

159

31%

*

90

36%

     Missing

-

(30)

(4)

(3)

(0)

Region

The geographical region where the deal took place

     Asia-Pacific

-

47

30%

51

32%

152

33%

78

36%

     Europe

-

42

26%

40

25%

91

20%

48

22%

     North America

-

54

34%

58

37%

175

39%

66

31%

     Others

-

17

11%

10

6%

36

8%

23

11%

     Missing

-

(67)

(34)

(64)

(39)

Molecule Type^c

With a drug/drug candidate of a specific molecule type

Gene/Cell Therapy

-

9

5%

14

7%

27

5%

10

4%

Protein

-

13

6%

11

6%

20

4%

16

6%

Vaccine

-

43

22%

30

17%

170

34%

***

72

29%

**

Anti-Body

-

30

15%

48

26%

121

24%

56

22%

Peptide

-

12

6%

10

5%

20

4%

6

2%

Small Molecule

-

98

50%

88

48%

155

31%

***

102

41%

Recombinant

-

16

8%

18

10%

48

10%

22

9%

Biologic

-

3

2%

4

2%

9

2%

8

3%

Oligonucleotide

-

8

4%

14

8%

33

7%

26

11%